Biolase (NSDQ:BLTI) issued a message to concerned investors, quashing rumors of CEO Federico Pignatelli’s imminent departure and asserting his continued leadership of the dental laser company.
Pignatelli took the reins at Biolase in 2010, announcing a voluntary $1 salary and 35,000 shares of company stock as his annual compensation, a commitment he’s re-upped ever since and challenged others to undertake, calling on political and corporate figures to tighten their own belts.
Following speculation that Pignatelli might depart, Biolase released a statement assuring investors that there is "absolutely no truth to rumors."
“I am fully committed to Biolase now and for the future,” Pignatelli said in prepared remarks.
T2 Biosystems appoints 2 senior officials
T2 Biosystems named 2 new senior officers as the company preps for launch of its flagship blood diagnostics product, the T2Candida.
New CFO Marc Jones was previously the finance chief of Crashlytics, which was acquired by Twitter during his tenure. T2 also named Dr. Frédéric Sweeney as senior director of business development from his former position at Tornado Spectral Systems.
Read more
Following a brief hiatus, Hospira CSO returns
Dr. Sumant Ramachandra will return to his role as chief scientific officer of Hospira (NYSE:HSP) after his departure earlier this year. Hospira CEO Michael Ball said many candidates were vetted for the slot, but Ramachandra was still the best fit, according to a company statement.
"I’m energized by the opportunity to return to Hospira – to rejoin the talented employees and exciting future that drew me to the company nearly 5 years ago. My short time away has reignited my passion for the tremendous opportunities ahead," Ramachandra said in the release.
Read more
New controller at Bioheart
Evelyn Flores will take over as corporate controller at Bioheart, bringing with her more than 15 years of private and public finance and accounting experience. Bioheart CEO Mike Tomas said Flores will help the company put new financial software systems in place.
"We are thrilled to have Ms. Flores join the Bioheart team. She brings a wealth of audit, accounting and compliance knowledge to our management team," Tomas said in prepared remarks.
Read more
SafeWire pulls in VP of Sales from J&J, DePuy
New senior VP of sales at SafeWire Sean Kane hails from 17 years of sales experience at medical device giants like Johnson & Johnson (NYSE:JNJ), DJ Ortho, DePuy OrthoTech and DePuy Synthes. Kane will take head the spinal orthopedics company’s global sales division and manage corporate marketing and strategy.
Read more
